0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Atrial Natriuretic Peptide in Congestive Heart Failure after Acute Myocardial Infarction

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The concentration of atrial natriuretic peptide, a newly discovered hormone produced in the atrial wall, was measured in 55 patients during the first 72 h after acute myocardial infarction. 37 patients became clinically congested, while 18 patients avoided this complication. 13 patients (9 congested and 4 uncongested) experienced tachycardia, known to raise the concentration of atrial natriuretic peptide both with and without congestive heart failure. In the remaining 42 patients, the congested group had a significantly higher plasma atrial natriuretic peptide concentration than the uncongested group (p < 0.05) on all 3 days. In the congested group the concentration of atrial natriuretic peptide did not normalize after initiation of treatment. We conclude that the concentration of atrial natriuretic peptide is increased in all patients with acute myocardial infarction and that the level of atrial natriuretic peptide declines during the first 24 h in all patients and normalizes in the uncongested patients while the level of atrial natriuretic peptide is still elevated (at least for 72 h) in the congested patients.

          Related collections

          Author and article information

          Journal
          CRD
          Cardiology
          10.1159/issn.0008-6312
          Cardiology
          S. Karger AG
          0008-6312
          1421-9751
          1993
          1993
          14 November 2008
          : 82
          : 1
          : 1-6
          Affiliations
          aDepartment of Clinical Chemistry and bDepartment of Cardiology and Internal Medicine, Svendborg Hospital, Svendborg, Denmark
          Article
          175846 Cardiology 1993;82:1–6
          10.1159/000175846
          8519004
          © 1993 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Categories
          General Cardiology

          Comments

          Comment on this article